Development of immunotherapy combination strategies in cancer by Parkes, EE, Yap, TA, Peng, W, Moyers, JT, Curran, MA, Tawbi, HA

“…SIGNIFICANCE: Although immune-checkpoint inhibitors are approved as dual checkpoint strategies, and in combination with cytotoxic chemotherapy and angiogenesis inhibitors for multiple cancers, patient benefit remains limited. …”

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer by Nicum, S, Strauss, V, McGregor, N, McNeish, I, Roux, R, Hall, M, Michael, A, Roberts, C

“…Olaparib is a potent PARP inhibitor that has shown enhanced activity in women with relapsed BRCA-mutated OC in both platinum sensitive and resistant settings. Angiogenesis inhibitors, such as the oral tyrosine kinase inhibitor cediranib, are active in OC, and have shown additive effects when combined with PARP inhibitors preclinically, as hypoxia-induced downregulation of homologous recombination repair genes, BRCA1, 2 and RAD51 enhances PARP inhibitor sensitivity. …”

The Roles of Vitamin D and Polyphenols in the Management of Age-Related Macular Degeneration: A Narrative Review by Nádia Fernandes, Marta Castro Araújo, Carla Lança

“…Polyphenols (flavonoids group, curcumin and resveratrol) seem to play an important role as angiogenesis inhibitors, but their effect on AMD is still unclear. …”
Get full text

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery by Ilaria Colombo, Katherine Karakasis, Sneha Suku, Amit M. Oza

“…The efficacy of immune checkpoint inhibitors as single agents or combined with chemotherapy has been unsatisfactory, leading to the exploration of alternative combination strategies with targeted agents (e.g., poly-ADP-ribose inhibitors (PARP)and angiogenesis inhibitors) and novel immunotherapy approaches. …”
Get full text

Angiogenesis as a Therapeutic Target in Endometriosis by Dusan Djokovic, Carlos Calhaz-Jorge

“…Discussion and Conclusion: The integration of anti-angiogenic approaches in the multimodal management strategies for endometriosis patients will be conditioned by the outcomes of future assessments regarding the effectiveness of such treatments, the risk of drug resistance development and the incidence of unacceptable side effects. Keywords: Angiogenesis Inhibitors/therapeutic use; Endometriosis/drug therapy. …”
Get full text

Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years by Julia E. Karrer, Luis Giovannoni, Gerd A. Kullak-Ublick, Stefan Weiler

“…Our aim was to quantify ADRs in ophthalmology in Switzerland, with a focus on angiogenesis inhibitors. METHODS Individual case safety reports (ICSRs) on suspected ADRs reported in Switzerland from January 1991 to June 2016 were extracted from the WHO Global ICSR database, VigiBase™. …”
Get full text

A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy by Becker, C

“…Systemic treatment with the angiogenesis inhibitors caplostatin and endostatin peptide mP-1 delayed and suppressed the onset and intensity of the luminescent signal. …”

Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner by Xie, Liang, Duncan, Michael B., Pahler, Jessica, Sugimoto, Hikaru, Martino, Margot, Lively, Julie, Mundel, Thomas, Soubasakos, Mary, Takeda, Takaaki, Inoue, Masahiro, Lawler, Jack, Hanahan, Douglas, Rubin, Kristofer, Kalluri, Raghu, Hynes, Richard O

“…Whereas the roles of proangiogenic factors in carcinogenesis are well established, those of endogenous angiogenesis inhibitors (EAIs) remain to be fully elaborated. …”
Get full text
Get full text

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers by Wioletta Olejarz, Grażyna Kubiak-Tomaszewska, Alicja Chrzanowska, Tomasz Lorenc

“…Combined strategies based on angiogenesis inhibitors and immunotherapy effectively enhances therapies in various cancers, but effective treatment requires further research.…”
Get full text

Marine Bromophenol Bis(2,3,6-Tribromo-4,5-Dihydroxybenzyl)ether Inhibits Angiogenesis in Human Umbilical Vein Endothelial Cells and Reduces Vasculogenic Mimicry in Human Lung Cance... by Songtao Dong, Zhongyuan Chen, Li Wang, Yankai Liu, Dimitrios Stagos, Xiukun Lin, Ming Liu

“…Anti-angiogenesis is one of the significant therapies in tumor treatment, while the clinical angiogenesis inhibitors usually exhibit endothelial cells dysfunction and drug resistance. …”
Get full text

Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis by Kyunghee Noh, Lingegowda S. Mangala, Hee-Dong Han, Ningyan Zhang, Sunila Pradeep, Sherry Y. Wu, Shaolin Ma, Edna Mora, Rajesha Rupaimoole, Dahai Jiang, Yunfei Wen, Mian M.K. Shahzad, Yasmin Lyons, MinSoon Cho, Wei Hu, Archana S. Nagaraja, Monika Haemmerle, Celia S.L. Mak, Xiuhui Chen, Kshipra M. Gharpure, Hui Deng, Wei Xiong, Charles V. Kingsley, Jinsong Liu, Nicholas Jennings, Michael J. Birrer, Richard R. Bouchard, Gabriel Lopez-Berestein, Robert L. Coleman, Zhiqiang An, Anil K. Sood

“…Summary: Angiogenesis inhibitors are important for cancer therapy, but clinically approved anti-angiogenic agents have shown only modest efficacy and can compromise wound healing. …”
Get full text

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions by Masahiro Kagabu, Takayuki Nagasawa, Chie Sato, Yasuko Fukagawa, Hanae Kawamura, Hidetoshi Tomabechi, Shuji Takemoto, Tadahiro Shoji, Tsukasa Baba

“…Since the introduction of angiogenesis inhibitors, treatment for recurrent and advanced cervical cancers has improved in the past five years, but median overall survival is 16.8 months for advanced cervical cancer, and all-stage five-year overall survival rate is 68%, indicating that treatment effects remain inadequate. …”
Get full text

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer by Maximilian Fleischmann, Georgios Chatzikonstantinou, Emmanouil Fokas, Jörn Wichmann, Hans Christiansen, Klaus Strebhardt, Claus Rödel, Nikolaos Tselis, Franz Rödel

“…Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. …”
Get full text

Normal Wound Healing and Tumor Angiogenesis as a Game of Competitive Inhibition by Kareva, Irina, Abou-Slaybi, Abdo, Dashevsky, Olga, Klement, Giannoula Lakka, Dodd, Oliver B.

“…The invasive wound-like edge of growing tumors has an overabundance of angiogenesis stimulators, and we propose that their abundance out-competes angiogenesis inhibitors, effectively preventing inhibition of angiogenesis and vessel maturation. …”
Get full text

Tumor endothelial cell-specific drug delivery system using apelin-conjugated liposomes. by Hiroki Kawahara, Hisamichi Naito, Kazuhiro Takara, Taku Wakabayashi, Hiroyasu Kidoya, Nobuyuki Takakura

“…BACKGROUND: A drug delivery system specifically targeting endothelial cells (ECs) in tumors is required to prevent normal blood vessels from being damaged by angiogenesis inhibitors. The purpose of this study was to investigate whether apelin, a ligand for APJ expressed in ECs when angiogenesis is taking place, can be used for targeting drug delivery to ECs in tumors. …”
Get full text

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. by Helfrich, I, Scheffrahn, I, Bartling, S, Weis, J, von Felbert, V, Middleton, M, Kato, M, Ergün, S, Augustin, H, Schadendorf, D

“…Clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway is still limited to date. …”

Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer by Haigang Ding, Haigang Ding, Juan Zhang, Juan Zhang, Feng Zhang, Feng Zhang, Yan Xu, Yijun Yu, Wenqing Liang, Qingping Li

“…With the advent of novel treatments such as angiogenesis inhibitors or immuno-checkpoint blockers in recent years, the survival rate of patients with advanced cervical cancer has significantly increased. …”
Get full text

The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy by Katarzyna Masłowska, Paweł Krzysztof Halik, Dagmara Tymecka, Aleksandra Misicka, Ewa Gniazdowska

“…It is known that vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs) play a pivotal role in angiogenesis process; hence, application of angiogenesis inhibitors can be an effective approach in anticancer combination therapeutic strategies. …”
Get full text

Real-Time Longitudinal Evaluation of Tumor Blood Vessels Using a Compact Preclinical Fluorescence Imaging System by Hoibin Jeong, Song-Rae Kim, Yujung Kang, Huisu Kim, Seo-Young Kim, Su-Hyeon Cho, Kil-Nam Kim

“…Conversely, these vascular parameters decreased when the mice were treated with angiogenesis inhibitors, which suggests that the effects of drugs targeting angiogenesis can be rapidly and easily screened. …”
Get full text

Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling by Qianhui Wu, Stacey D. Finley

“…Therefore, it is important to understand the dynamics of eNOS signaling in the context of angiogenesis inhibitors. Thrombospondin-1 (TSP1) is an important angiogenic inhibitor that, through interaction with its receptor CD47, has been shown to redundantly inhibit eNOS signaling. …”
Get full text